Keyword: Praluent

Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.

Amgen's aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market didn't work, but the big biotech hasn't given up.

Aimovig has several more hurdles to clear before it can reach its lofty blockbuster goals—including persuading payers it's worth the cost.

Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.

Formulary shutouts were already hurting Sanofi's diabetes numbers. But price cuts and Medicare compounded the pain in the first quarter of 2017.

Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?

Sanofi and Regeneron presented Odyssey outcomes data for Praluent at ACC 2018 Saturday.

Sanofi and Regeneron may have had a successful year with Dupixent—approved in March to treat atopic dermatitis—but there's much more to come.